Evidence map›Paper›PMID 30643440›Full record

ArticleInfection and drug resistance2019

Molecular epidemiology of ESBL-producing

Laure Surgers, Peter Boersma, Pierre-Marie Girard, Audrey Homor, Delphine Geneste, Guillaume Arlet, Dominique Decré, Anders Boyd

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Infection and drug resistance, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. High Prevalence of ST131 Subclades C2-Frontiers in cellular and infection microbiology · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Laure SurgersInfectious Diseases Department, Saint-Antoine Hospital, APHP, Paris, France, laure.surgers@aphp.fr.
Peter BoersmaDepartment of Epidemiology and Community Health, University of Minnesota, Minneapolis, MN, USA.
Pierre-Marie GirardInfectious Diseases Department, Saint-Antoine Hospital, APHP, Paris, France, laure.surgers@aphp.fr.
Audrey HomorBacteriology Department, Saint-Antoine Hospital, APHP, Paris, France.
Delphine GenesteSorbonne University, INSERM, U1135, Centre d'Immunologie et des Maladies Infectieuses, CIMI Team 13, Paris, France, laure.surgers@aphp.fr.
Guillaume ArletSorbonne University, INSERM, U1135, Centre d'Immunologie et des Maladies Infectieuses, CIMI Team 13, Paris, France, laure.surgers@aphp.fr.
Dominique DecréSorbonne University, INSERM, U1135, Centre d'Immunologie et des Maladies Infectieuses, CIMI Team 13, Paris, France, laure.surgers@aphp.fr.
Anders BoydINSERM, Sorbonne Université, Institut Pierre Louis d'Épidémiologie et de Santé Publique, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo genetically characterize clusters of virulence factors (VFs) among extended spectrum β-lactamase (ESBL)-producing

methodsOne hundred forty-eight

resultsCTX-M was the predominant ESBL and susceptibility to trimethoprim-sulfamethoxazole (32%), ciprofloxacin (22%) and aminoglycosides (32%) was low. In

conclusionDistinct clusters of

Indexed as

E. coliESBLK. pneumoniaemortalityvirulence

Identifiers

PMID30643440
PMCPMC6318714

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.